南通南平电子科技有限公司

福建佰孟医学科技有限公司（简称：佰孟医学），是由一群归国海外学者共同创立，并与国内外多家享有盛誉的生命科学企业合作成立。作为福建省在生命科学与转化医学研究领域的先驱，佰孟医学是一家集研发、销售和服务为一体的高新技术企业。公司专注于生命科学研究、新药研发筛选、临床转化医学研究以及环境和工业应用等多个领域，提供高质量的生命科学基础研究产品、卓越的生物技术服务以及生物信息大数据的整体解决方案。通过这些努力，佰孟医学成功塑造了生物医学行业内的知名品牌。

河南筑瓴建筑有限公司

河南筑瓴建筑有限公司，公司规模为少于50人，公司类型为民营公司，所属行业为建筑/建材/工程。

颖奕国际医疗

ENHANCE INTERNATIONAL MEDICAL CENTER
Hainan | YINGYI INTERNATIONAL MEDICAL CENTER

YINGYI INTERNATIONAL MEDICAL CENTER obtained the special medical practice access permit in Boao Lecheng International Medical Tourism Pilot Zone of Hainan Province in 2015. The construction of YINGYI INTERNATIONAL MEDICAL CENTER started in 2019. It is a third-level comprehensive hospital covering an area of 80 mu with a total construction area of 63,000 square meters. The hospital features a full-range human cell tissue storage library for cell sample freezing, a GTP-level thousand-grade cell preparation center, and a medical imaging center providing DR, MRI, CT, ultrasound, and other examinations, dedicated to offering customers more precise medical imaging diagnosis services. It is a modern new comprehensive treatment hospital with a precision medical molecular diagnosis laboratory, clean operating rooms of grade hundred, thousand, and ten thousand levels, and 300 beds. The main departments under construction in Phase I include sports medicine and rehabilitation center, preventive medicine center, health management center, anti-aging and medical aesthetics center, and chronic disease management center. The full-range human cell tissue storage library and cGMP-level cell preparation center, medical imaging center providing DR, MRI, CT, ultrasound, and testing center providing precision medical molecular detection, gene detection, proteomics detection, intestinal flora detection, functional medicine, and other detection services are committed to providing customers with more accurate medical diagnosis services. The main departments under construction in the first phase such as sports medicine department and rehabilitation center, tumor prevention and treatment center, anti-aging and medical aesthetics center, preventive medicine center, chronic disease management center, etc., are expected to open for business on February 1, 2021.

Global technology integration includes:
U.S. Caladrius Biosciences, Inc. (NASDAQ: CLBS)
U.S. Regenexx Corporate
U.S. CTABioman Biotechnology Group (NASDAQ: CBMG)
U.S. Aspire Lifestyles
U.S. Aspine Health Group
Germany TICEBA GmbH
South Korea Biosolution Co., Ltd
North America Cabo San Lucas Diamante
Taiwan Taipei Veterans General Hospital
China Medical University Affiliated Hospital

上海江夏血液技术有限公司

上海江夏血液技术有限公司专注于***吸附产品的研发、生产和销售，主要产品包括脑卒中治疗滤器和脑卒中预防滤器。其中，脑卒中治疗滤器具备全国独有的脑梗死治疗适应症血液净化疗法，此技术在国内领先，达到国际先进水平。

公司获得卫计委直属的“吴阶平医学基金会”临床科研专项资助基金课题项目以及世界中医药学会联合会课题立项项目的双重支持，助力市场推广。

秉持“塑造一流产品，服务人类健康”的企业文化，公司致力于通过责任立业，稳步实现梦想，计划在三年内实现在A股上市。